Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
RESEARCH TOOLSreports
Holding CNTA?
Track your performance easily
CNTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.65 - $18.97
Previous Close$17.16
Volume791.27K
Average Volume (3M)548.97K
Market Cap
$2.31B
Enterprise Value$1.88B
Total Cash (Recent Filing)$518.45M
Total Debt (Recent Filing)$84.14M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 27, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding131,845,476
10 Day Avg. Volume713,370
30 Day Avg. Volume548,966
Standard Deviation0.18
R-Squared0.17
Alpha-0.00297
Financial Highlights & Ratios
Price to Book (P/B)4.53
Price to Sales (P/S)337.65
Price to Cash Flow (P/CF)-27.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.32K
Enterprise Value/Gross Profit273.79
Enterprise Value/Ebitda-11.87
Forecast
1Y Price Target
$28.50Price Target Upside66.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Centessa Pharmaceuticals News
PremiumCompany Announcements
Centessa Pharmaceuticals Strengthens Financial Position Amid Losses
PremiumCompany Announcements
Centessa Pharmaceuticals Advances Pipeline with Promising OX2R Data
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentORX750's efficient development could allow it to surpass competitors and become first-in-class, highlighting its strong competitive edge.
Efficacy And SafetyThe strong efficacy and safety profile of ORX750 drives high confidence in its opportunity, suggesting it can become a best-in-class product in a significant market.
Market PotentialNT1/NT2/IH could be a $5B+ market opportunity, with a preference for a single drug treatment and no anticipated need for combination therapy with ORX750.
Bears Say
Clinical TrialsThe 25 mg dose of ALKS 2680 is hindered by the presentation of adverse events.
Financial ImpactSerpinPC’s discontinuation is expected to result in $200M in net savings.
Product PipelineThe company’s discontinuation of the pivotal SerpinPC program in HemeB.
---
Ownership Overview
1.82% Insiders
8.15% Mutual Funds
66.19% Other Institutional Investors
23.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $6.65 and its highest was $18.97 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Currently, no data Available
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is Mar 27, 2025 which is in 96 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.026.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -$0.42.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 131,845,470 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went up 1.614%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Among the largest hedge funds holding Centessa Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Centessa Pharmaceuticals’s shares valued at 100M.
---
Centessa Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (66.08% Upside)
$28.50 (66.08% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.95%
12-Months-Change
Fundamentals
Return on Equity
-42.73%
Trailing 12-Months
Asset Growth
61.57%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.
---
CNTA Stock 12 Month Forecast
Average Price Target
$28.50
▲(66.08% Upside)
Technical Analysis
Best Analysts Covering CNTA
1 Year
1 Year Success Rate
16/16 ratings generated profit
1 Year Average Return
+98.20%
reiterated a buy rating last month
Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +98.20% per trade.
---